Pharmaceuticals News and Research

RSS

Noven Pharmaceuticals files ANDA with FDA for approval of generic version of Exelon

Noven Pharmaceuticals, Inc. today confirmed that it has filed an Abbreviated New Drug Application with the U.S. Food and Drug Administration seeking approval to market its rivastigmine transdermal system in 4.6 mg/24 hours and 9.5 mg/24 hours dosage strengths.

4 Apr 2013

Viewpoints: Obama's brain initiative is 'modest but welcome start;' Disability insurance facing 'immediate crisis'

President Obama officially announced his new brain research initiative on Tuesday, with a pledge to put $100 million in his 2014 budget to support work at three federal agencies.

4 Apr 2013

Tris Pharma gets FDA NDA approval for Karbinal ER Extended-release Oral Suspension

Tris Pharma, a specialty pharmaceutical company focused on developing innovative drug delivery technologies, today announced that the U.S. Food and Drug Administration has approved its New Drug Application for Karbinal ER (carbinoxamine maleate) Extended-release Oral Suspension 4mg/5ml, the first sustained-release histamine receptor blocking agent indicated for the treatment of seasonal and perennial allergic rhinitis in children ages 2 and up.

4 Apr 2013

FDA approves Mylan's ANDA for generic version of Zovirax Ointment

Mylan Inc. today announced that its subsidiary Mylan Pharmaceuticals has received final approval from the U.S. Food and Drug Administration for its Abbreviated New Drug Application for Acyclovir Ointment USP, 5%.

4 Apr 2013

CRG researchers reprogramme lymphoma and leukaemia cells to halt malignancy

Researchers from the Centre for Genomic Regulation (CRG) in Barcelona reprogramme lymphoma and leukaemia cells to halt their malignancy. Resulting cells remain benign even when no longer subjected to treatment and reduce likelihood of developing new tumours.

3 Apr 2013

Ulcerative colitis and Crohn’s disease treatments: an interview with Dr Parikh, vice president, general medicine, Takeda

Ulcerative colitis (UC) and Crohn’s disease (CD) are both relapsing and remitting chronic diseases of bowel inflammation. By that I mean they flare and physicians try to get the flare under control and try to induce remission. However, despite a number of treatments available, they tend to relapse.

From Takeda 3 Apr 2013

Isis Pharmaceuticals starts ISIS-APOARx Phase 1 clinical study for treatment of atherosclerosis

Isis Pharmaceuticals, Inc. announced today that it has initiated a Phase 1 clinical study for ISIS-APOARx, an antisense drug targeting apolipoprotein(a) for the treatment of atherosclerosis.

3 Apr 2013

Oramed Pharmaceuticals receives Japanese patent for innovative oral delivery technology

Oramed Pharmaceuticals Inc., a developer of oral drug delivery systems, announced today that it has received approval for a key patent by the Japanese Patent Office.

3 Apr 2013

BIND Therapeutics and Pfizer sign collaboration agreement to develop, commercialize Accurins

BIND Therapeutics, a clinical-stage biopharmaceutical company developing a new class of highly selective targeted and programmable therapeutics called Accurins, announced today that it has entered into a global collaboration agreement with Pfizer Inc. to develop and commercialize Accurins utilizing select small molecule targeted therapies.

3 Apr 2013

Media outlets examine reaction to India's Supreme Court ruling on Novartis patent case

"In a decisive victory for India's pharmaceutical industry, India's Supreme Court rejected Novartis' patent application for the cancer drug Glivec on Monday, ending a seven-year battle by the Swiss drug maker to get a patent in India on its powerful leukemia drug," Time reports (Mahr, 4/1).

3 Apr 2013

First patient dosed in second Phase 2 study with LiRIS for treatment of Interstitial Cystitis

TARIS Biomedical, a specialty pharmaceutical company developing innovative, targeted therapies to treat bladder diseases with high unmet medical need, announced today that it has dosed the first patient in its second Phase 2 clinical study with LiRIS, its novel product candidate, in patients with Interstitial Cystitis.

3 Apr 2013

Study shows cholesterol rafts can shepherd genetic payloads into cancer cells

DNA, siRNA and miRNA can reprogram cancer cells - that is, if these nucleic acids could cross through the cell membrane. A University of Colorado Cancer Center study published today in the journal Therapeutic Delivery shows that cholesterol "rafts" can shepherd genetic payloads into cancer cells.

3 Apr 2013

Microbiology testing services now offered by Ceram

Ceram, the international materials testing and development company, has announced that it is now offering microbiology testing services for the healthcare industries, thanks to a partnership with a leading UK microbiological testing lab.

2 Apr 2013

Revance Therapeutics raises $33M in Series E financing

Revance Therapeutics, Inc., a privately held specialty biopharmaceutical company developing novel botulinum toxin products for use in aesthetic and therapeutic indications, today announced that it has raised $33 million of its Series E growth financing.

2 Apr 2013

NewLink Genetics starts Phase 2 clinical study of indoximod in patients with metastatic breast cancer

NewLink Genetics Corporation, a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced the initiation of a double-blind, randomized, placebo-controlled Phase 2 clinical study of its first IDO (indoleamine-(2,3)-dioxygenase) pathway inhibitor, indoximod, in patients with metastatic breast cancer.

2 Apr 2013

N30 Pharmaceuticals presents preclinical data of GSNORi at European Cystic Fibrosis Society meeting

N30 Pharmaceuticals, Inc., a clinical stage, biopharmaceutical company focused on the development of therapies for cystic fibrosis, announced today the presentation of key preclinical data for its novel inhibitors of S-nitrosoglutathione reductase.

2 Apr 2013

Inovio Pharmaceuticals reports release of phase II clinical trial results of ChronVac-C

Inovio Pharmaceuticals, Inc. today announced the release of preliminary clinical trial results by its collaborator ChronTech AS of their open label phase II clinical study of ChronVac-C, ChronTech's vaccine to treat hepatitis C virus infection.

2 Apr 2013

Ampio Pharmaceuticals receives FDA IND approval to start clinical trial of Ampion

Ampio Pharmaceuticals, Inc. today announced FDA acceptance of its IND and the treatment of the first fifteen (15) patients in its clinical trial using Ampion™ to treat osteoarthritis of the knee.

2 Apr 2013

Report highlights ecological cost of pharmaceutical waste

Pharmaceuticals commonly found in the environment are disrupting streams, with unknown impacts on aquatic life and water quality.

2 Apr 2013

India's Supreme Court rules against Novartis AG in 'landmark' patent case

"India's Supreme Court on Monday rejected drug maker Novartis AG's attempt to patent an updated version of a cancer drug in a landmark decision that health activists say ensures poor patients around the world will get continued access to cheap versions of lifesaving medicines," the Associated Press reports.

2 Apr 2013

Pharmaceuticals News and Research

Noven Pharmaceuticals files ANDA with FDA for approval of generic version of Exelon

Viewpoints: Obama's brain initiative is 'modest but welcome start;' Disability insurance facing 'immediate crisis'

Tris Pharma gets FDA NDA approval for Karbinal ER Extended-release Oral Suspension

FDA approves Mylan's ANDA for generic version of Zovirax Ointment

CRG researchers reprogramme lymphoma and leukaemia cells to halt malignancy

Ulcerative colitis and Crohn’s disease treatments: an interview with Dr Parikh, vice president, general medicine, Takeda

Isis Pharmaceuticals starts ISIS-APOARx Phase 1 clinical study for treatment of atherosclerosis

Oramed Pharmaceuticals receives Japanese patent for innovative oral delivery technology

BIND Therapeutics and Pfizer sign collaboration agreement to develop, commercialize Accurins

Media outlets examine reaction to India's Supreme Court ruling on Novartis patent case

First patient dosed in second Phase 2 study with LiRIS for treatment of Interstitial Cystitis

Study shows cholesterol rafts can shepherd genetic payloads into cancer cells

Microbiology testing services now offered by Ceram

Revance Therapeutics raises $33M in Series E financing

NewLink Genetics starts Phase 2 clinical study of indoximod in patients with metastatic breast cancer

N30 Pharmaceuticals presents preclinical data of GSNORi at European Cystic Fibrosis Society meeting

Inovio Pharmaceuticals reports release of phase II clinical trial results of ChronVac-C

Ampio Pharmaceuticals receives FDA IND approval to start clinical trial of Ampion

Report highlights ecological cost of pharmaceutical waste

India's Supreme Court rules against Novartis AG in 'landmark' patent case

Pittcon Highlights: Pharmaceutical & Biologic eBook

Latest eBooks

A practical guide to lipid nanoparticle formulation and resizing

Editorial Focus eBook - Spatial and single-cell omics (1st edition)

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Improving healthcare sustainability through carbon data

Managing vibration in IVF laboratories

A New Approach to Preventing Bladder Cancer Recurrence